Avanza Fonder AB Boosts Stake in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Avanza Fonder AB increased its holdings in Regeneron Pharmaceuticals by 9.4% in Q2, now owning 9,737 shares valued at $5.1 million.
• Regeneron reported EPS of $12.89 for the quarter, exceeding estimates of $8.43, with revenue of $3.68 billion, up 3.6% year-over-year.
• After a recent quarterly dividend announcement, Regeneron’s annualized dividend yield stands at 0.6%, with a payout ratio of 8.87%.

Avanza Fonder AB raised its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 9.4% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 9,737 shares of the biopharmaceutical company's stock after buying an additional 838 shares during the period. Avanza Fonder AB's holdings in Regeneron Pharmaceuticals were worth $5,112,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Pinney & Scofield Inc. purchased a new stake in Regeneron Pharmaceuticals in the 4th quarter valued at about $25,000. E Fund Management Hong Kong Co. Ltd. increased its stake in Regeneron Pharmaceuticals by 344.4% in the 1st quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock valued at $25,000 after buying an additional 31 shares during the last quarter. Activest Wealth Management increased its stake in Regeneron Pharmaceuticals by 110.5% in the 1st quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company's stock valued at $25,000 after buying an additional 21 shares during the last quarter. Costello Asset Management INC purchased a new stake in Regeneron Pharmaceuticals in the 1st quarter valued at about $27,000. Finally, Saudi Central Bank purchased a new stake in shares of Regeneron Pharmaceuticals during the 1st quarter worth approximately $27,000. Hedge funds and other institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Price Performance

NASDAQ REGN traded up $3.69 on Monday, hitting $595.68. The stock had a trading volume of 904,767 shares, compared to its average volume of 1,099,036. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $1,154.56. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60. The company has a market capitalization of $63.14 billion, a price-to-earnings ratio of 15.01, a price-to-earnings-growth ratio of 1.98 and a beta of 0.35. The firm has a 50-day moving average of $567.77 and a 200-day moving average of $574.26.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, topping the consensus estimate of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The business had revenue of $3.68 billion for the quarter, compared to analysts' expectations of $3.30 billion. During the same period in the prior year, the company posted $11.56 EPS. The business's revenue for the quarter was up 3.6% compared to the same quarter last year. Equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th were given a dividend of $0.88 per share. The ex-dividend date was Monday, August 18th. This represents a $3.52 annualized dividend and a dividend yield of 0.6%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is 8.87%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the stock. Raymond James Financial upgraded shares of Regeneron Pharmaceuticals to a "moderate buy" rating in a research note on Tuesday, September 2nd. Wells Fargo & Company lowered shares of Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $580.00 price target for the company. in a research note on Friday, August 1st. UBS Group reissued a "neutral" rating on shares of Regeneron Pharmaceuticals in a report on Friday, August 1st. Rothschild & Co Redburn initiated coverage on shares of Regeneron Pharmaceuticals in a research note on Thursday, August 14th. They issued a "buy" rating and a $890.00 target price for the company. Finally, Guggenheim upped their price target on shares of Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the company a "buy" rating in a research note on Friday, August 1st. Three equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $817.67.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.